Share on LinkedInShare on LinkedIn

ARTICLE · 07 MAY 2026

Santen Revisited – CJEU Asked To Think Again On “first Authorisation” For SPCs

A new referral to the Court of Justice of the EU will once again consider what is meant by the “first marketing authorisation” requirement of Article 3(d) of the EU medicines SPC Regulation. Specifically, the CJEU has been asked to clarify whether a veterinary marketing authorisation (MA) for a medicine can be considered the “first” MA for SPC purposes when there has been a prior MA for the same product as a human medicine.

United KingdomIntellectual Property

A new referral to the Court of Justice of the EU will once again consider what is meant by the “first marketing authorisation” requirement of Article 3(d) of the EU medicines SPC Regulation. Specifically, the CJEU has been asked to clarify whether a veterinary marketing authorisation (MA) for a medicine can be considered the “first” MA for SPC purposes when there has been a prior MA for the same product as a human medicine. 

Background – SPC Regulation and earlier CJEU decisions on “first” marketing authorisation

Article 3(b) of the EU medicinal products SPC Regulation (469/2009) requires a valid marketing authorisation (MA) for the product for which an SPC is sought, under the relevant EU Directive (2001/83/EC for human medicines or 2001/82/EC for veterinary medicines).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from